IHC - CD79a

The pain experienced during the biopsy procedure varies depending on the site from where the tissue sample is obtained. Local or general anesthesia is often used to minimize discomfort.

A positive result means that the CD79a protein is present in the tissue sample, which is indicative of a B-cell lymphoma or leukemia.

A negative result means that the CD79a protein was not detected in the tissue sample. This could indicate that the patient does not have a B-cell lymphoma or leukemia, or the disease might be in a stage where the protein is not expressed.

Yes, the IHC - CD79a test may be used to monitor the response to treatment in certain B-cell lymphomas and leukemias. Changes in CD79a expression can be indicative of the effectiveness of the treatment.

The primary risk associated with this test is related to the biopsy procedure. This can include pain, infection, and bleeding at the biopsy site.

Yes, while the IHC - CD79a test is highly specific for B-cells, not all B-cell lymphomas and leukemias will express CD79a. Therefore, a negative result does not definitively rule out these conditions.

There are typically no dietary restrictions before the test, but follow any specific instructions given by your healthcare provider.

The results are typically available within 2 to 4 days, but this can vary depending on the laboratory.

Coverage for the IHC - CD79a test depends on your insurance plan. It's recommended to check with your insurance provider before undergoing the test.

In a normal tissue sample, B-cells expressing CD79a should be present. However, the number and distribution of these cells depend on the specific tissue and the individual's health status.

Other tests that might be performed along with the IHC - CD79a test include other immunohistochemistry tests for different cell markers, genetic tests, and additional pathology tests to help establish a diagnosis.

Certain medications can affect the immune system and may alter the distribution of B-cells in tissue samples. It's important to inform your healthcare provider of any medications you are taking.

This test is often ordered by a healthcare provider for patients with suspected B-cell lymphomas or leukemias. If you have symptoms suggestive of these conditions, your doctor might recommend this test.

The IHC - CD79a test is typically performed on a tissue sample obtained through a biopsy. The type of biopsy (needle, core, or surgical) depends on the suspected location of the disease.

After the biopsy procedure, you need to follow your healthcare provider's instructions for wound care to prevent infection and promote healing. It is also important to look out for any potential complications such as excessive bleeding, fever, or severe pain.

Factors that can influence the results of the IHC - CD79a test include the quality of the tissue sample, the stage of the disease, the individual's overall health, and the individual's use of certain medications.

Yes, the IHC - CD79a test can be performed on children if there is a clinical suspicion of B-cell lymphoma or leukemia. The decision to test a child is made by the healthcare provider based on the child's symptoms, clinical history, and physical examination findings.

Yes, other tests such as flow cytometry, cytogenetic analysis, or molecular genetic tests can also be used to diagnose B-cell lymphomas or leukemias. However, each test has its own advantages and limitations, and the choice of test depends on the individual patient's situation.